<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00814619</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 41/07</org_study_id>
    <secondary_id>SWS-SAKK-41-07</secondary_id>
    <secondary_id>EudraCT-2008-006012-38</secondary_id>
    <secondary_id>EU-20894</secondary_id>
    <secondary_id>CDR0000629101</secondary_id>
    <nct_id>NCT00814619</nct_id>
  </id_info>
  <brief_title>Capecitabine and Radiation Therapy With or Without Panitumumab in Treating Patients With Advanced Rectal Cancer</brief_title>
  <official_title>Neoadjuvant Radiotherapy and Capecitabine With or Without Panitumumab in Patients With Advanced, K-ras Unmutated Rectal Cancer. A Randomized Multicenter Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop
      the growth of tumor cells, either by killing the cells or by stopping them from dividing.
      Giving radiation therapy that uses a 3-dimensional (3-D) image of the tumor to help focus
      thin beams of radiation directly on the tumor, and giving radiation therapy in higher doses
      over a shorter period of time, may kill more tumor cells and have fewer side effects.
      Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some
      block the ability of tumor cells to grow and spread. Others find tumor cells and help kill
      them or carry tumor-killing substances to them. It is not yet known whether giving
      capecitabine together with 3-D conformal radiation therapy is more effective with or without
      panitumumab in treating patients with advanced rectal cancer.

      PURPOSE: This randomized phase II trial is studying giving capecitabine together with
      radiation therapy to see how well it works with or without panitumumab in treating patients
      with advanced rectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To assess the efficacy and safety of neoadjuvant capecitabine and concurrent
           3-dimensional conformal radiotherapy with vs without panitumumab in patients with
           advanced K-ras unmutated rectal cancer.

      OUTLINE: This is a multicenter study. Patients are stratified according to participating
      center, T stage (T3 vs T4), tumor localization measured from caudal part of the tumor to the
      anocutaneous line (&lt; 10 cm vs ≥ 10 cm), and number of EGFR gene copies (&lt; 2.9 vs ≥ 2.9).
      Patients are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients receive panitumumab IV over 30-90 minutes on days 1, 15, 29, 43, and 57
           and oral capecitabine twice daily on days 8-40. Beginning on day 8, patients undergo
           daily fractions of 3-D conformal radiotherapy 5 days a week for 5 weeks. Beginning
           approximately 6 weeks after completion of panitumumab and chemoradiotherapy, patients
           undergo surgery.

        -  Arm II: Patients receive oral capecitabine twice daily on days 1-33. Patients undergo
           concurrent 3-D conformal radiotherapy 5 days a week for 5 weeks. Beginning 6 weeks after
           completion of chemoradiotherapy, patients undergo surgery.

      After completion of study therapy, patients are followed periodically for up to 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete or near-complete response (Dworak grade 3 and 4)</measure>
    <time_frame>after 13 weeks.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathological response</measure>
    <time_frame>after 13 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 or R1 resection</measure>
    <time_frame>after 13 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications (within 8 weeks after surgery)</measure>
    <time_frame>within 8 weeks after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to local relapse</measure>
    <time_frame>calculated from randomization to documented relapse or censored at the last CT and/or endorectal ultrasound without local relapse.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to distant failure</measure>
    <time_frame>calculated from randomization to documented distant (metastatic) failure or censored at the last CT without distant (metastatic) failure.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>calculated from randomization to first relapse or death (whichever occurs first).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>All AEs will be assessed according to NCI CTCAE v3.0.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive panitumumab IV over 30-90 minutes on days 1, 15, 29, 43, and 57 and oral capecitabine twice daily on days 8-40. Beginning on day 8, patients undergo daily fractions of 3-D conformal radiotherapy 5 days a week for 5 weeks. Beginning approximately 6 weeks after completion of panitumumab and chemoradiotherapy, patients undergo surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive oral capecitabine twice daily on days 1-33. Patients undergo concurrent 3-D conformal radiotherapy 5 days a week for 5 weeks. Beginning 6 weeks after completion of chemoradiotherapy, patients undergo surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>panitumumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Vectibix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <description>Patients undergo surgical resection</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>3-dimensional conformal radiation therapy</intervention_name>
    <description>Patients undergo radiotherapy</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed advanced adenocarcinoma of the rectum with or without nodal
             involvement

               -  Stage mrT3-4 and/or mrN1-2, M0

               -  Tumors must express wild type K-ras gene

          -  No distant metastasis

        PATIENT CHARACTERISTICS:

          -  WHO performance status 0-1

          -  Able to undergo surgery

          -  ANC ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Hemoglobin ≥ 100 g/L

          -  Creatinine clearance ≥ 50 mL/min

          -  AST ≤ 2.5 times upper limit normal (ULN)

          -  Total bilirubin ≤ 1.5 times ULN

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must agree to use effective contraception during and for 12 months
             after completion of study

          -  No malignancy within the past 5 years with the exception of adequately treated
             cervical carcinoma in situ or localized nonmelanoma skin cancer

          -  No psychiatric disorder that would preclude understanding study-related information,
             giving informed consent, or complying with oral drug intake

          -  No prior existing conditions that would preclude radiotherapy

          -  No clinically significant (i.e., active) cardiac disease (e.g., congestive heart
             failure, symptomatic coronary artery disease, and cardiac arrhythmia even if
             controlled with medication) or myocardial infarction within the past 12 months

          -  No lack of physical integrity of the upper gastrointestinal tract or malabsorption
             syndrome

          -  No serious underlying medical condition that, in the judgement of the investigator,
             could impair the ability of the patient to participate in the trial (e.g., active
             autoimmune disease or uncontrolled diabetes)

          -  No known dihydropyrimidine dehydrogenase deficiency

          -  No known hypersensitivity to trial drugs or hypersensitivity to any other component of
             the trial drugs

        PRIOR CONCURRENT THERAPY:

          -  More than 30 days since prior treatment in a clinical trial

          -  No other concurrent experimental drugs, anticancer therapy, or investigational
             treatments

          -  No prior treatment for rectal cancer

          -  No prior anti-EGFR antibody therapy (e.g., cetuximab) or small-molecule EGFR
             inhibitors (e.g., erlotinib hydrochloride)

          -  No concurrent treatment with brivudine, lamivudine, ribavirin, or any other nucleoside
             analogues

          -  No organ allografts

          -  No concurrent drugs contraindicated for use with the trial drugs

          -  No other concurrent anti-EGFR-targeting agents

          -  No other concurrent radiotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Helbling, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Onkozentrum Zürich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Szent Laszlo Korhaz</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hirslanden Klinik Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>CH-5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>CH-5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baden</name>
      <address>
        <city>Baden</city>
        <zip>CH-5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Claraspital AG</name>
      <address>
        <city>Basel</city>
        <zip>CH-4016</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital-Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico della Svizzera Italiana</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalzentrum Biel</name>
      <address>
        <city>Biel</city>
        <zip>CH-2501</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Bruderholz</name>
      <address>
        <city>Bruderholz</city>
        <zip>CH-4101</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubuenden</name>
      <address>
        <city>Chur</city>
        <zip>CH-7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cantonal Universitaire de Geneve</name>
      <address>
        <city>Geneva</city>
        <zip>CH-1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital, Luzerne</name>
      <address>
        <city>Luzerne</city>
        <zip>CH-6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OnkoZentrum Luzern at Klinik St. Anna</name>
      <address>
        <city>Luzern</city>
        <zip>6006</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Olten</name>
      <address>
        <city>Olten</city>
        <zip>CH-4600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Regional de Sion-Herens-Conthey</name>
      <address>
        <city>Sion</city>
        <zip>CH -1951</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital - St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionalspital</name>
      <address>
        <city>Thun</city>
        <zip>3600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur</name>
      <address>
        <city>Winterthur</city>
        <zip>CH-8400</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkozentrum</name>
      <address>
        <city>Zurich</city>
        <zip>8038</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Hirslanden</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital Triemli</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitaetsSpital Zuerich</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Helbling D, Bodoky G, Gautschi O, Sun H, Bosman F, Gloor B, Burkhard R, Winterhalder R, Madlung A, Rauch D, Saletti P, Widmer L, Borner M, Baertschi D, Yan P, Benhattar J, Leibundgut EO, Bougel S, Koeberle D. Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07. Ann Oncol. 2013 Mar;24(3):718-25. doi: 10.1093/annonc/mds519. Epub 2012 Nov 8.</citation>
    <PMID>23139259</PMID>
  </results_reference>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 24, 2008</study_first_submitted>
  <study_first_submitted_qc>December 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2008</study_first_posted>
  <last_update_submitted>April 29, 2014</last_update_submitted>
  <last_update_submitted_qc>April 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the rectum</keyword>
  <keyword>stage III rectal cancer</keyword>
  <keyword>stage II rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

